IDBS, a global provider of innovative data management, analytics and modeling solutions, announced that it will provide a unique, enterprise translational medicine platform for the Integrated Cancer Centre at King’s Health Partners. The Oncology Research Information System, (ORIS), designed at the Integrated Cancer Centre and developed and delivered by IDBS, will enable King’s Health Partners to develop targeted, personalized, cancer therapies according to the specific genetic and other characteristics of individual patients. This will improve the likelihood and number of successful treatment outcomes.
ORIS is the first of its kind: a single cross-organizational research platform that will bring together patient data for all King’s Health Partner’s cancer cases, accounting for a quarter of hospital beds in London. This comprehensive approach to cancer research has never before been able to be handled in one IT platform. ORIS will provide a unique translational medicine hub, handling the complex analytical demands of translational research and improving collaboration between the partners – King’s College London University, King’s College Hospital, Guy’s and St Thomas’ and South London and the Maudsley NHS Foundation Trusts.
IDBS, through the ORIS platform and associated organizational changes, will provide King’s Health Partners with:
• improved cancer treatment through secure knowledge sharing of patient outcome information;
• one secure searchable hub for clinical, diagnostic, pathological, sample, research and genomics centric information integrated from multiple sources;
• highly secure information governance and pseudonymization procedures to protect patient confidentiality;
• comprehensive scientific and statistical analytics to support requirements across research, teaching and clinical needs;
• reduced complexity with high security through scalable, flexible hosting and rigorous access control;
• powerful visualization of translational research data and an evaluation of data quality;
• an enhanced competitive position for attracting pharmaceutical and other research partners.
“Despite all the progress medical science has made, many cancer patients are still treated with protocols identified through a process of trial and error. Our aim is to change this through a targeted approach to cancer therapy, which will improve outcomes and patient quality of life,” said Professor Peter Parker, PhD, FRS, Head of the Division of Cancer Studies and R&D Lead for the Integrated Cancer Centre at King’s Health Partners. “Critical to this effort is a new collaboration between the different research and healthcare organizations involved and, above all, access to relevant data and analytics to enable our multi-disciplinary research teams to deliver outcome-based therapies.”
“During our extensive competitive tender process, IDBS clearly demonstrated a unique understanding of the complexities of translational medicine, core software provision and solution integration that we required for this program,” continued Professor Parker.
“IDBS understands that the improvement of patient outcomes will come from the successful delivery of targeted treatments, which requires a fundamental change in the approach healthcare organizations take to using increasingly complex research information and sharing of the clinical knowledge they generate,” said Neil Kipling, founder and CEO of IDBS. “Our broad understanding of the healthcare and pharmaceutical research sectors enables us to deliver the enabling technologies required to make the promise of personalized medicine a reality. The ORIS project further validates our strategy to design and build enterprise data management and analytics systems targeted at improving healthcare provision in the UK and worldwide.”
This is the first step in a five-year strategic relationship that could eventually expand to cover all disease areas including all oncology disorders and cardiovascular disease.
IDBS www.idbs.com/
